EGFR and lung adenocarcinoma: Given the high rate of EGFR mutations in Chinese lung adenocarcinoma patients, a previous study [22] has demonstrated that exon 19 and 21 mutations combined with clinicopathological features could be a molecular marker to assess the efficacy of TKI treatment for NSCLC.